In April 2011, RBM was acquired by Myriad Genetics ($80M in cash) and now operates as Myriad RBM Inc, a wholly owned subsidiary. Rules-Based Medicine Inc (RBM) had focused on the development and commercialization of molecular diagnostic tests based on novel biomarker patterns primarily for the psychiatric market. The firm developed molecular diagnostic test panels using its proprietary multi-analyte profiling, or MAP, a technology that helps to screen large sets of well-characterized clinical samples from diseased and non-diseased populations against its menu of biomarker tests. The company also provides testing products and services, including MAP testing services, custom MAP services, multiplexed immunoassay kits, and TruCulture and other co-culture services to the pharmaceutical, biotechnology, and medical research industries
